Mymetics Corporation (MYMETICS CORPORATION) aksje

Mymetics Corporation engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company's product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, and malaria. Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; and national institutes of health. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.